NASDAQ:SCPH scPharmaceuticals (SCPH) Stock Price, News & Analysis $2.50 -0.10 (-3.85%) As of 04/24/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About scPharmaceuticals Stock (NASDAQ:SCPH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get scPharmaceuticals alerts:Sign Up Key Stats Today's Range$2.48▼$2.5950-Day Range$2.02▼$3.6852-Week Range$1.94▼$5.65Volume229,903 shsAverage Volume356,145 shsMarket Capitalization$125.71 millionP/E RatioN/ADividend YieldN/APrice Target$14.00Consensus RatingBuy Company OverviewscPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.Read More… scPharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks78th Percentile Overall ScoreSCPH MarketRank™: scPharmaceuticals scored higher than 78% of companies evaluated by MarketBeat, and ranked 259th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingscPharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragescPharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about scPharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for scPharmaceuticals are expected to grow in the coming year, from ($1.53) to ($1.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of scPharmaceuticals is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of scPharmaceuticals is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioscPharmaceuticals has a P/B Ratio of 2.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about scPharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.20% of the float of scPharmaceuticals has been sold short.Short Interest Ratio / Days to CoverscPharmaceuticals has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.Change versus previous monthShort interest in scPharmaceuticals has recently decreased by 14.99%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldscPharmaceuticals does not currently pay a dividend.Dividend GrowthscPharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.08 Percentage of Shares Shorted10.20% of the float of scPharmaceuticals has been sold short.Short Interest Ratio / Days to CoverscPharmaceuticals has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.Change versus previous monthShort interest in scPharmaceuticals has recently decreased by 14.99%, indicating that investor sentiment is improving significantly. News and Social Media2.7 / 5News Sentiment0.94 News SentimentscPharmaceuticals has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for scPharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for SCPH on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added scPharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, scPharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.52% of the stock of scPharmaceuticals is held by insiders.Percentage Held by Institutions89.52% of the stock of scPharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about scPharmaceuticals' insider trading history. Receive SCPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for scPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SCPH Stock News HeadlinesAnalysts Are Bullish on These Healthcare Stocks: scPharmaceuticals (SCPH), Sarepta Therapeutics (SRPT)April 23 at 9:37 PM | markets.businessinsider.comCraig-Hallum Sticks to Its Buy Rating for scPharmaceuticals (SCPH)March 22, 2025 | markets.businessinsider.comCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess. The news is screaming fear. But while most traders watch their portfolios tank…April 25, 2025 | Crypto Swap Profits (Ad)scPharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results with Major FDA Approval for FUROSCIXMarch 22, 2025 | nasdaq.comscPharmaceuticals Full Year 2024 Earnings: In Line With ExpectationsMarch 21, 2025 | finance.yahoo.comscPharmaceuticals price target lowered to $12 from $20 at MaximMarch 21, 2025 | markets.businessinsider.comQ4 2024 scPharmaceuticals Inc Earnings CallMarch 20, 2025 | finance.yahoo.comscPharmaceuticals reports Q 4EPS (35c), consensus (39c)March 20, 2025 | markets.businessinsider.comSee More Headlines SCPH Stock Analysis - Frequently Asked Questions How have SCPH shares performed this year? scPharmaceuticals' stock was trading at $3.54 at the start of the year. Since then, SCPH stock has decreased by 29.4% and is now trading at $2.50. View the best growth stocks for 2025 here. How were scPharmaceuticals' earnings last quarter? scPharmaceuticals Inc. (NASDAQ:SCPH) released its quarterly earnings results on Wednesday, March, 19th. The company reported ($0.35) EPS for the quarter, beating analysts' consensus estimates of ($0.40) by $0.05. The business earned $12.15 million during the quarter, compared to the consensus estimate of $12.08 million. scPharmaceuticals had a negative net margin of 264.60% and a negative trailing twelve-month return on equity of 244.93%. Read the conference call transcript. When did scPharmaceuticals IPO? scPharmaceuticals (SCPH) raised $96 million in an initial public offering (IPO) on Friday, November 17th 2017. The company issued 6,400,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO. Who are scPharmaceuticals' major shareholders? Top institutional shareholders of scPharmaceuticals include Rhumbline Advisers (0.10%) and Assenagon Asset Management S.A. (0.02%). Insiders that own company stock include Orbimed Advisors Llc and 5Am Partners Iv, Llc. View institutional ownership trends. How do I buy shares of scPharmaceuticals? Shares of SCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of scPharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that scPharmaceuticals investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), AUO (AUOTY), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings3/19/2025Today4/24/2025Next Earnings (Estimated)5/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SCPH CIK1604950 Webwww.scpharma.com Phone(617) 517-0730FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$14.00 High Stock Price Target$18.00 Low Stock Price Target$12.00 Potential Upside/Downside+460.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,810,000.00 Net Margins-264.60% Pretax Margin-264.60% Return on Equity-244.93% Return on Assets-68.56% Debt Debt-to-Equity Ratio1.66 Current Ratio8.08 Quick Ratio6.89 Sales & Book Value Annual Sales$36.33 million Price / Sales3.46 Cash FlowN/A Price / Cash FlowN/A Book Value$1.04 per share Price / Book2.40Miscellaneous Outstanding Shares50,284,000Free Float47,278,000Market Cap$125.71 million OptionableOptionable Beta0.38 10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:SCPH) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding scPharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share scPharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.